Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05322980
Other study ID # summary-500g
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 5, 2022
Est. completion date December 31, 2022

Study information

Verified date November 2023
Source Nagano Children's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a retrospective single-center cohort study. The comparison in short- and long-term outcomes will be made between those with and without primary microcephaly in infants weighing ≤ 500 g.


Description:

This is a retrospective single-center cohort study. The study setting is a level IV neonatal intensive care unit (NICU) at Nagano Children's Hospital in Nagano, Japan. We will retrospectively collect the data of those who were admitted to Nagano Children's Hospital NICU between January 1, 2015, and December 31, 2019. Eligible infants will be identified using our neonatal database and clinical records. The extracted data includes maternal background information and clinical course, infant's status at birth, the clinical course in NICU, and the follow-up data at 6 and 18 months of corrected age. Among the eligible infants, those with a z score of birth head circumference < -2 will be classified into the Microcephaly group and others into the Control group. The z score is calculated using the Japanese growth standard.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Live-born infants weighing = 500 g at birth - Infants whose clinical course is available in the electronic medical record Exclusion Criteria: - Stillbirths - Infants who received only palliative care at birth - Outborn infants - Infants whose assessment at 3 years of age not completed at data analysis

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Microcephaly
Those with a z score of birth head circumference < -2 (primary microcephaly) are classified into the Microcephaly group.

Locations

Country Name City State
Japan Nagano Children's Hospital Azumino Nagano

Sponsors (1)

Lead Sponsor Collaborator
Nagano Children's Hospital

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of neurodevelopmental impairment Having at least one of the following conditions: cognitive impairment, cerebral palsy, visual impairment, or hearing impairment. Cognitive impairment was defined as a modified DQ score of = 70 using the Kyoto Scale of Psychological Development. CP was defined as (1) a non-progressive disorder of the central nervous system appearing in the early years of life and clinically characterized by a persistent but not unchanging impairment of movement and posture and/or (2) the Gross Motor Function Classification System level = II. Visual impairment was defined as unilateral or bilateral blindness, or any other condition requiring corrective lenses, which were diagnosed or determined by ophthalmologists. Hearing impairment was defined as unilateral or bilateral hearing loss that requires a hearing aid. The diagnosis of hearing loss was made by otolaryngologists using auditory steady-state response. 3 years of age
Secondary Survival rate Survival rate is the proportion of those have survived. At discharge from neonatal intensive care unit, an average at 40 weeks' postmenstrual age.
Secondary Rate of severe bronchopulmonary dysplasia The definition of bronchopulmonary dysplasia proposed by the National Institute of Child Health and Human Development is used to classify the severity of bronchopulmonary dysplasia. Those who need = 30% of oxygen or any mechanical respiratory support at 36 weeks of gestation are classified as having severe bronchopulmonary dysplasia. At 36 weeks' postmenstrual age
Secondary Rate of need for surgery for patent ductus arteriosus Patent ductus arteriosus is diagnosed by neonatologists using echocardiography and clinical signs. In neonatal intensive care unit, an average of up to 4 weeks of life
Secondary Rate of severe intraventricular hemorrhage Intraventricular hemorrhage is diagnosed by neonatologists using head ultrasound. Severe IVH was defined as grade III or IV by the classification of Papile. In neonatal intensive care unit, an average of up to 2 weeks of life
Secondary Rate of periventricular leukomalacia Periventricular leukomalacia is diagnosed using head ultrasound or magnetic resonance imaging, typically cysts formation in the periventricular white matter. In neonatal intensive care unit, an average of up to 40 weeks' postmenstrual age
Secondary Rate of necrotizing enterocolitis The diagnosis with necrotizing enterocolitis. In neonatal intensive care unit, an average of up to 2 weeks of life
Secondary Rate of sepsis Sepsis is defined as septicemia or bacteremia with a positive culture result of the blood and/or cerebrospinal fluid. In neonatal intensive care unit, an average of up to 4 weeks of life
Secondary Rate of need for treatment for retinopathy of prematurity The diagnosis of retinopathy of prematurity and the decision on the need for treatment were made by ophthalmologic examination. In neonatal intensive care unit, an average of up to 40 weeks' postmenstrual age
Secondary Weight Physical measurement. At 40 weeks' postmenstrual age or at discharge (approximately 40 weeks' postmenstrual age)
Secondary Length Physical measurement. At 40 weeks' postmenstrual age or at discharge (approximately 40 weeks' postmenstrual age)
Secondary Head circumference Physical measurement. At 40 weeks' postmenstrual age or at discharge (approximately 40 weeks' postmenstrual age)
Secondary Postmenstrual age Postmenstrual age is calculated based on their gestational age and date at birth. At discharge, an average at 40 weeks' postmenstrual age
Secondary Need for home oxygen therapy Need for home oxygen therapy. At discharge, an average at 40 weeks' postmenstrual age
Secondary Tracheostomy Need for tracheostomy. In neonatal intensive care unit, an average at 40 weeks' postmenstrual age
Secondary Length of hospital stay The initial hospitalization. In neonatal intensive care unit, an average at 40 weeks' postmenstrual age
Secondary Survival rate Survival rate is the proportion of those have survived. At 3 years of age
Secondary Modified developmental quotient Modified developmental quotient is calculated by dividing developmental age (measured by the Kyoto Scale of Psychological Development) by the corrected age. At 3 years of age
Secondary Rate of cerebral palsy Cerebral palsy is defined as (1) a non-progressive disorder of the central nervous system appearing in early years of life and clinically characterized by a persistent but not unchanging impairment of movement and posture and/or (2) the Gross Motor Function Classification System level = II. At 3 years of age
Secondary Rate of visual impairment Visual impairment is defined as unilateral or bilateral blindness, or any other condition requiring corrective lenses, which were diagnosed or determined by ophthalmologists. At 3 years of age
Secondary Rate of hearing impairment Hearing impairment is defined as unilateral or bilateral hearing loss that requires a hearing aid. The diagnosis of hearing loss was made by otolaryngologists using auditory steady-state response. At 3 years of age
Secondary Rate of those who need home oxygen therapy Need for home oxygen therapy. At 3 years of age
Secondary Rate of those who need tracheostomy Need for tracheostomy. At 3 years of age
Secondary Rate of those who need tube feeding or gastrostomy Need for tube feeding or gastrostomy. At 3 years of age
Secondary Rate of those who need rehospitalization Need for rehospitalization. After 18 months of corrected age unit until 3 years of age
Secondary Weight Physical measurement. At 3 years of age
Secondary Height Physical measurement. At 3 years of age
Secondary Head circumference Physical measurement. At 3 years of age
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT02510170 - Fetal and Maternal Head Circumference During Pregnancy in Israeli Population N/A
Completed NCT01565005 - Microcephaly Genetic Deficiency in Neural Progenitors N/A
Terminated NCT03922594 - Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
Completed NCT02943304 - Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
Recruiting NCT06019182 - MEHMO Natural History and Biomarkers
Completed NCT03330600 - Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome N/A
Recruiting NCT03255369 - Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
Recruiting NCT03325946 - The FBRI VTC Neuromotor Research Clinic
Completed NCT02741882 - Zika and Microcephaly: Case-control Study N/A
Recruiting NCT05518188 - Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) Phase 1/Phase 2
Recruiting NCT03651687 - Guangzhou Surveillance and Clinical Study in Microcephaly (GSCSM)
Completed NCT00001639 - Evaluation of Patients With Unresolved Chromosome Abnormalities N/A
Withdrawn NCT01151462 - Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
Completed NCT04816175 - Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay N/A